Miami, Florida
Cancer biologic therapy trials in Miami, FL
34 cancer biologic therapy studies are recruiting participants at sites in Miami as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Miami at a glance
- 34 studies are recruiting at a site in Miami.
- By phase: Early Phase 1 (1), Phase 1 (1), Phase 1/2 (5), Phase 2 (13), Phase 2/3 (1), Phase 3 (13).
- By sponsor: industry (15), government (11), university, hospital or other (8).
- By research area: Lymphoma (13), Lung Cancer (11), Breast Cancer (6), Melanoma (4).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Miami
Basic details from each study's public record (the 30 most recently updated of 34). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT05564377 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT06876714 · updated
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BriaCell Therapeutics Corporation
- Study sites
- University Of Miami-SCCC-Miami · University of Miami_SCCC - Kendall
- Registry record
- NCT06072612 · updated
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Greenwich LifeSciences, Inc.
- Study site
- University of Miami - Sylvester Comprehensive Cancer Center
- Registry record
- NCT05232916 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Miami, FL on ClinicalTrials.gov.
Lung cancer studies recruiting in Miami
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Miami Cancer Institute
- Registry record
- NCT06498635 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Miami Cancer Institute at Baptist Health, Inc. ( Site 0214)
- Registry record
- NCT06623422 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT06096844 · updated
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07099898 · updated
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Obsidian Therapeutics, Inc.
- Study site
- University of Miami
- Registry record
- NCT06060613 · updated
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study site
- University of Miami
- Registry record
- NCT06667908 · updated
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Phase 3
- All ages
- All sexes
- Sponsor
- Pierre Fabre Medicament
- Study site
- University of Miami/Jackson Memorial Hospital (Adults only)
- Registry record
- NCT03394365 · updated
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
- Registry record
- NCT06780137 · updated
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Phase 1/2
- Ages 18 to 70
- All sexes
- Sponsor
- Iovance Biotherapeutics, Inc.
- Study site
- Sylvester Comprehensive Cancer Center
- Registry record
- NCT05361174 · updated
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Genelux Corporation
- Study sites
- Bioresearch Partner · University of Miami - Sylvester Comprehensive Cancer Center
- Registry record
- NCT06463665 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Miami, FL on ClinicalTrials.gov.
Melanoma studies recruiting in Miami
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- University of Miami - Sylvester Comprehensive Cancer Cente
- Registry record
- NCT06743126 · updated
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT05896839 · updated
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- University of Miami Hospital and Clinics
- Registry record
- NCT03686124 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Miami, FL on ClinicalTrials.gov.
Lymphoma studies recruiting in Miami
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT06337318 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Nicklaus Children's Hospital
- Registry record
- NCT05675410 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- Miami Cancer Institute at Baptist Health, Inc.
- Registry record
- NCT06500273 · updated
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AIDS Malignancy Consortium
- Study site
- University of Miami Miller School of Medicine
- Registry record
- NCT04139304 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT06124157 · updated
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Izidore Lossos, MD
- Study site
- University of Miami
- Registry record
- NCT06796998 · updated
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- UM Sylvester Comprehensive Cancer Center at Kendall · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT05886036 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study sites
- Nicklaus Children's Hospital · University of Miami Miller School of Medicine-Sylvester Cancer Center
- Registry record
- NCT03959085 · updated
DALY II USA/ MB-CART2019.1 for DLBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Miltenyi Biomedicine GmbH
- Study site
- Baptist Health Miami Cancer Institute
- Registry record
- NCT04792489 · updated
CD4CAR for CD4+ Leukemia and Lymphoma
- Phase 1
- Ages 12 and older
- All sexes
- Sponsor
- Huda Salman
- Study site
- University of Miami Sylvester Comprehensive Cancer Center
- Registry record
- NCT03829540 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Miami, FL on ClinicalTrials.gov.
Ask about studies near Miami
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Florida
All Florida locations
126 studies recruiting across 65 cities.
Tampa
53 studies recruiting.
Jacksonville
39 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections